12000 results for "cancer rna-seq"

in 21.97 milliseconds.

• Small RNA sequencing from CSF extracellular vesicles - PD/CTR

  The dataset contains FASTQ files referring to the study "Small RNA sequencing from CSF extracellular vesicles - PD/CTR". For this project, RNA was isolated from CSF extracellular vesicles obtained by ultracentrifugation. Libraries were prepared with the TruSeq Small RNA library prep Illumina, and sequencing conducted in the Illumina HiSeq4000.

  Dataset EGAD00001006629

• Next generation sequencing of diffuse intrinsic pontine glioma samples to identify recurrent mutations, variations, and expression patterns to define novel therapies

  Diffuse intrinsic pontine glioma (DIPG) is an extremely rare (~350 cases/year) and universally fatal childhood brain cancer. Standard clinical strategies such as chemotherapy and radiotherapy show only transient improvement in patient condition and result in negligible change in survival, DIPG remains at below 1% survival after 5 years. Prioritization of panobinostat through previous cooperative work resulted in a phase 1 clinical trial. Nonetheless, new therapies for DIPG must be identified to further dramatically change the statistics for DIPG. To identify novel therapy strategies for DIPG, we performed whole exome(16 new samples, 22 previously published samples, 38 in total with 26 matched normal) and RNA deep sequencing (17 new samples, 11 previously published samples) on a cohort of new patient samples. Sequencing results aid in the identification of recurrent mutations/variations and endotypic expression profiling to identify new therapeutic and treatment strategies for DIPG.

  Study phs001526

• MP2PRT-MNG: Identifying Novel Molecular Markers of Response to Radiotherapy in Meningiomas Using Samples from the RTOG-0539 (NCT00895622)

  The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. NRG RTOG (Radiation Therapy Oncology Group)-0539, which was a nonrandomized phase II cooperative group trial in 2009, was selected for inclusion in this program. NRG RTOG-0539 assigned patients with histologically confirmed diagnosis of meningioma to 1 of 3 risk groups based on 2007 WHO grade, resection extent, and recurrence status, and radiotherapy was given per protocol to the intermediate- and high-risk cases. Under the MP2PRT program, DNA methylation profiling, RNA sequencing, and whole exome sequencing were performed on clinical trial cases with available tissue for molecular analyte extraction and subsequent sequencing. Raw molecular data with metadata are available for this study.

  Study phs003707

• Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: CheckMate 649 biomarker analyses

  First-line nivolumab-plus-chemotherapy demonstrated superior overall survival (OS) versus chemotherapy for advanced gastroesophageal adenocarcinoma (CheckMate 649). Nivolumab-plus-ipilimumab provided durable responses and higher survival rates versus chemotherapy; however, the prespecified OS significance boundary was not met. To identify biomarkers predictive of differential efficacy outcomes, exploratory analyses were performed using whole-exome sequencing and RNA sequencing. Nivolumab-based therapies demonstrated improved efficacy versus chemotherapy in hypermutated and, to a lesser degree, Epstein Bar Virus-positive tumors compared with chromosomally unstable and genomically stable tumors. Within the KRAS-altered subgroup, only patients treated with nivolumab-plus-chemotherapy demonstrated improved OS benefit versus chemotherapy. Low stroma gene expression signature scores were associated with OS benefit with nivolumab-based regimens; high regulatory T-cell signatures were associated with OS benefit only with nivolumab-plus-ipilimumab. Our analyses suggest that distinct and overlapping pathways contribute to the efficacy of nivolumab-based regimens in gastroesophageal adenocarcinoma.

  Study EGAS50000000747

• Epigenomics and Single-cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis

  Langerhans cell histiocytosis (LCH) is a rare neoplasm predominantly affecting children. It occupies a hybrid position between cancers and inflammatory diseases, and it provides an attractive model for studying cancer development. To explore the molecular mechanisms underlying the pathophysiology of LCH and its characteristic clinical heterogeneity, we investigated the transcriptomic and epigenomic diversity in primary LCH lesions. Using single-cell RNA sequencing, we identified multiple recurrent types of LCH cells within these biopsies, including putative LCH progenitor cells and several subsets of differentiated LCH cells. We confirmed the presence of proliferative LCH cells in all analysed biopsies using immunohistochemistry, and we defined an epigenomic and gene-regulatory basis of the different LCH cell subsets by chromatin accessibility profiling. In summary, our single-cell analysis of LCH uncovered an unexpected degree of cellular, transcriptomic, and epigenomic heterogeneity among LCH cells, indicative of complex developmental hierarchies in LCH lesions.

  Study EGAS00001003822

• Comprehensive Genomic and Transcriptomic Analysis of Rare Cancers for Guiding of Therapy (H021)

  Here we analyzed the molecular profiles and clinical outcomes of 1,310 patients (proportion of rare cancers, 75%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. Based on 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved response and disease control rates (23.9% and 55.3%, respectively) compared to previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients.

  Study EGAS00001004813

• The Proteogenomic Subtypes of Acute Myeloid Leukemia

  Acute myeloid leukemia (AML) is an aggressive blood cancer with poor prognosis. We report a comprehensive proteogenomic analysis of bone-marrow biopsies from 252 uniformly treated AML patients to elucidate the molecular pathophysiology of AML in order to inform future diagnostic and therapeutic approaches. In addition to in-depth quantitative proteomics, our analysis includes cytogenetic profiling and DNA/RNA sequencing. We identify five proteomic AML subtypes, each reflecting specific biological features spanning genomic boundaries. Two of these proteomic subtypes correlate with patient outcome, but none are exclusively associated with specific genomic aberrations. Remarkably, one subtype (Mito-AML), which is only captured in the proteome, is characterized by high expression of mitochondrial proteins and confers poor outcome, with reduced remission rate and shorter overall survival upon treatment with intensive induction chemotherapy. Functional analyses reveal that Mito-AML is metabolically wired towards stronger complex I dependent respiration and is more responsive to treatment with the BCL2 inhibitor venetoclax.

  Study EGAS00001005950

• RNA sequencing of 12 NSCLC samples from 4 patients at MDACC

  Multi-region RNA sequencing of 12 NSCLC samples from 4 patients at MDACC

  Study EGAS00001005951

• CITE-seq raw count matrix

  Raw count matrix for CITE-seq data of PBMC collected from 113 patients.

  Dataset EGAD50000000141

• Raw count matrix scRNA-seq

  Raw count matrix for scRNA-seq data of PBMC collected from 113 patients.

  Dataset EGAD50000000142

• Targeted PacBio long-read scRNA-seq

  Twist custom capture–based targeted PacBio long-read scRNA-seq datasets for human adrenal sampleA and sampleB

  Dataset EGAD50000002212

• Reference epigenome Fat-adipocyte03 miRNA-Seq data generated from KEP study

  Fat-adipocyte03 miRNA-Seq single end data

  Dataset EGAD00001007190

• Reference epigenome KNIH010 miRNA-seq data generated from KEP study

  A KNIH010 miRNA-seq single end data for podocytes

  Dataset EGAD00001002769

• Reference epigenome Pancreas-Islet06 miRNA-Seq data generated from KEP study

  Pancreas-Islet06 miRNA-Seq single end data

  Dataset EGAD00001007187

• Reference epigenome Fat-adipocyte04 miRNA-Seq data generated from KEP study

  Fat-adipocyte04 miRNA-Seq single end data

  Dataset EGAD00001007191

• Reference epigenome Fat-adipocyte05 miRNA-Seq data generated from KEP study

  Fat-adipocyte05 miRNA-Seq single end data

  Dataset EGAD00001007192

• Reference epigenome Pancreas-Islet07 miRNA-Seq data generated from KEP study

  Pancreas-Islet07 miRNA-Seq single end data

  Dataset EGAD00001007188

• Reference epigenome Islet-derived_MSC08 miRNA-Seq data generated from KEP study

  Islet-derived_MSC08 miRNA-Seq single end data

  Dataset EGAD00001007882

• Single-cell DNA-seq

  Single-cell DNA sequencing (scDNA-seq) data.

  Dataset EGAD00001008779

• Reference epigenome Islet-derived_iPSC04 miRNA-Seq data generated from KEP study

  Islet-derived_iPSC04 miRNA-Seq single end data

  Dataset EGAD00001007883

• oxBS-seq for APL

  Oxidative bisulfite sequencing (oxBS-Seq) for APL

  Dataset EGAD00001008135

• Dataset for iAMP21 scRNA-seq

  10x Genomics 5' library scRNA-seq data for 4 iAMP21 patients

  Dataset EGAD00001009504

• Reference epigenome Pancreas-Islet08 miRNA-Seq data generated from KEP study

  Pancreas-Islet08 miRNA-Seq single end data

  Dataset EGAD00001007189

• Reference epigenome Islet-derived_iPSC04 mRNA-Seq data generated from KEP study

  Islet-derived_iPSC04 mRNA-Seq paired end data

  Dataset EGAD00001007880

• Reference epigenome Islet-derived_MSC08 mRNA-Seq data generated from KEP study

  Islet-derived_MSC08 mRNA-Seq paired end data

  Dataset EGAD00001007879